| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
62,030,000 |
| Market
Cap: |
276.03(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.48 - $21.47 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
| Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
11 |
| Total Shares Sold |
168,303 |
293,400 |
293,400 |
298,772 |
| Total Sell Value |
$3,127,242 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
| Total People Sold |
4 |
5 |
5 |
5 |
| Total Sell Transactions |
6 |
11 |
11 |
12 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bonvini Ezio |
Senior VP, Research |
• – – |
2014-10-09 |
4 |
OE |
$0.71 |
$1,891 |
D/D |
2,663 |
32,490 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2014-10-08 |
4 |
OE |
$0.94 |
$1,501 |
D/D |
1,597 |
29,827 |
|
- |
|
| Wigginton Jon Marc |
Sr V.P., Clinical |
• – – |
2014-10-01 |
4 |
AS |
$20.48 |
$102,400 |
D/D |
(5,000) |
0 |
|
- |
|
| Wigginton Jon Marc |
Sr V.P., Clinical |
• – – |
2014-10-01 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
5,000 |
|
- |
|
| Risser Eric Blasius |
VP, Business Development |
• – – |
2014-09-02 |
4 |
AS |
$20.89 |
$173,721 |
D/D |
(8,316) |
5,000 |
|
- |
|
| Wigginton Jon Marc |
Senior VP, Clinical Dev. |
• – – |
2014-08-18 |
4 |
AS |
$20.52 |
$102,600 |
D/D |
(5,000) |
0 |
|
- |
|
| Wigginton Jon Marc |
Senior VP, Clinical Dev. |
• – – |
2014-08-18 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
5,000 |
|
- |
|
| Risser Eric Blasius |
VP, Business Development |
• – – |
2014-06-30 |
4 |
AS |
$21.84 |
$174,720 |
D/D |
(8,000) |
13,316 |
|
- |
|
| Risser Eric Blasius |
VP, Business Development |
• – – |
2014-06-30 |
4 |
OE |
$0.94 |
$7,520 |
D/D |
8,000 |
21,316 |
|
- |
|
| Saran Atul |
See RemarksOfficer |
• – – |
2014-06-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,500 |
|
- |
|
| Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
• – – |
2014-05-29 |
4 |
S |
$19.75 |
$216,184 |
D/D |
(10,946) |
43,205 |
|
- |
|
| Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
• – – |
2014-05-29 |
4 |
OE |
$0.71 |
$7,772 |
D/D |
10,946 |
54,151 |
|
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical |
• – – |
2014-04-01 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
5,000 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2014-03-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
500 |
|
- |
|
| Hurwitz Edward |
Director |
– • – |
2014-02-18 |
4 |
S |
$36.50 |
$11,260,725 |
I/I |
(308,513) |
1,704,996 |
|
- |
|
| Oronsky Arnold L |
Director |
– • – |
2014-02-18 |
4 |
S |
$36.50 |
$7,300,000 |
I/I |
(200,000) |
1,708,716 |
|
- |
|
| Holmes W Stephen |
10% Owner |
– – • |
2013-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,908,716 |
1,908,716 |
|
- |
|
| Coulter James G |
Former 10% Owner |
– – – |
2013-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
2,208,762 |
2,208,762 |
|
- |
|
| Alta Embarcadero Biopharma Partners III Llc |
10% Owner |
– – • |
2013-10-16 |
4 |
OE |
$0.00 |
$0 |
I/I |
15,314 |
2,013,509 |
|
- |
|
| Alta Embarcadero Biopharma Partners III Llc |
10% Owner |
– – • |
2013-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,998,195 |
1,998,195 |
|
- |
|
| Galbraith Kenneth |
Director |
– • – |
2013-10-16 |
4 |
OE |
$0.00 |
$0 |
I/I |
15,315 |
1,317,049 |
|
- |
|
| Galbraith Kenneth |
Director |
– • – |
2013-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,254,859 |
1,301,734 |
|
- |
|
| Galbraith Kenneth |
Director |
– • – |
2013-10-16 |
4 |
B |
$16.00 |
$750,000 |
I/I |
46,875 |
46,875 |
2.1 |
- |
|
| Oronsky Arnold L |
Director |
– • – |
2013-10-16 |
4 |
OE |
$0.00 |
$0 |
I/I |
2,448 |
1,908,716 |
|
- |
|
| Oronsky Arnold L |
Director |
– • – |
2013-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,906,268 |
1,906,268 |
|
- |
|
310 Records found
|
|
Page 12 of 13 |
|
|
0.07 (1.6%) 
